Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

J. ten Berg; D. Sibbing; B. Rocca; E. Van Belle; B. Chevalier; J.P. Collet; D. Dudek; M. Gilard; D.A. Gorog; J. Grapsa; E.L. Grove; P. Lancellotti; A.S. Petronio; A. Rubboli; L. Torracca; G. Vilahur; A. Witkowski; J. Mehilli

doi:10.1093/eurheartj/ehab196

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

J. ten Berg^*, D. Sibbing, B. Rocca, E. Van Belle, B. Chevalier, J.P. Collet, D. Dudek, M. Gilard, D.A. Gorog, J. Grapsa, E.L. Grove, P. Lancellotti, A.S. Petronio, A. Rubboli, L. Torracca, G. Vilahur, A. Witkowski, J. Mehilli

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.[GRAPHICS].

Original language	English
Pages (from-to)	2265-2269
Number of pages	5
Journal	European Heart Journal
Volume	42
Issue number	23
DOIs	https://doi.org/10.1093/eurheartj/ehab196
Publication status	Published - 14 Jun 2021

Keywords

Transcatheter aortic valve implantation
Antithrombotic treatment
ANTIPLATELET THERAPY

Access to Document

10.1093/eurheartj/ehab196

Fingerprint

Dive into the research topics of 'Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease'. Together they form a unique fingerprint.

Cite this

ten Berg, J., Sibbing, D., Rocca, B., Van Belle, E., Chevalier, B., Collet, J. P., Dudek, D., Gilard, M., Gorog, D. A., Grapsa, J., Grove, E. L., Lancellotti, P., Petronio, A. S., Rubboli, A., Torracca, L., Vilahur, G., Witkowski, A., & Mehilli, J. (2021). Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal, 42(23), 2265-2269. https://doi.org/10.1093/eurheartj/ehab196

ten Berg, J. ; Sibbing, D. ; Rocca, B. et al. / Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. In: European Heart Journal. 2021 ; Vol. 42, No. 23. pp. 2265-2269.

@article{71e2b11b4efb4bcf90287c4d0539e381,

title = "Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease",

abstract = "Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.[GRAPHICS].",

keywords = "Transcatheter aortic valve implantation, Antithrombotic treatment, ANTIPLATELET THERAPY",

author = "{ten Berg}, J. and D. Sibbing and B. Rocca and {Van Belle}, E. and B. Chevalier and J.P. Collet and D. Dudek and M. Gilard and D.A. Gorog and J. Grapsa and E.L. Grove and P. Lancellotti and A.S. Petronio and A. Rubboli and L. Torracca and G. Vilahur and A. Witkowski and J. Mehilli",

year = "2021",

month = jun,

day = "14",

doi = "10.1093/eurheartj/ehab196",

language = "English",

volume = "42",

pages = "2265--2269",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "23",

}

ten Berg, J, Sibbing, D, Rocca, B, Van Belle, E, Chevalier, B, Collet, JP, Dudek, D, Gilard, M, Gorog, DA, Grapsa, J, Grove, EL, Lancellotti, P, Petronio, AS, Rubboli, A, Torracca, L, Vilahur, G, Witkowski, A & Mehilli, J 2021, 'Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease', European Heart Journal, vol. 42, no. 23, pp. 2265-2269. https://doi.org/10.1093/eurheartj/ehab196

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. / ten Berg, J.; Sibbing, D.; Rocca, B. et al.
In: European Heart Journal, Vol. 42, No. 23, 14.06.2021, p. 2265-2269.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

AU - ten Berg, J.

AU - Sibbing, D.

AU - Rocca, B.

AU - Van Belle, E.

AU - Chevalier, B.

AU - Collet, J.P.

AU - Dudek, D.

AU - Gilard, M.

AU - Gorog, D.A.

AU - Grapsa, J.

AU - Grove, E.L.

AU - Lancellotti, P.

AU - Petronio, A.S.

AU - Rubboli, A.

AU - Torracca, L.

AU - Vilahur, G.

AU - Witkowski, A.

AU - Mehilli, J.

PY - 2021/6/14

Y1 - 2021/6/14

N2 - Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.[GRAPHICS].

AB - Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.[GRAPHICS].

KW - Transcatheter aortic valve implantation

KW - Antithrombotic treatment

KW - ANTIPLATELET THERAPY

U2 - 10.1093/eurheartj/ehab196

DO - 10.1093/eurheartj/ehab196

M3 - Editorial

C2 - 33822924

SN - 0195-668X

VL - 42

SP - 2265

EP - 2269

JO - European Heart Journal

JF - European Heart Journal

IS - 23

ER -

ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal. 2021 Jun 14;42(23):2265-2269. doi: 10.1093/eurheartj/ehab196